Therapeutic peptides

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S324000

Reexamination Certificate

active

07449302

ABSTRACT:
The present invention provides a ligand isolated fromMoraxella catarrhalisouter membrane protein which binds to CEACAM receptors, said ligand comprising a receptor binding domain comprising an amino acid sequence selected from the group disclosed, or a fragment, homologue, functional equivalent, derivative, degenerate or hydroxylation, sulphonation or glycosylation product or other secondary processing product thereof. The invention also provides medicaments and vaccines comprising said ligand, and their use in the treatment or prophylaxis of infection. Also provided is a screening method for the identification of novel therapeutic compounds.

REFERENCES:
patent: WO 98/28333 (1998-07-01), None
Philippe N'Guessan; The USPA1 protein ofM. catarrhalisinduces CEAMA-1 dependent apoptosis in alverolar epithelial cells. Inflamm. Res. Supp(2), S74, A13, 2007.
Database EMBL, Sequence of UspA1, retrieved from EBI, Database accession No. Q9XD56, XP002273230 (1999).
Hill et al., “A novel-cell-binding mechanism ofMoraxella catarrhalisubiquitous surface protein UspA: specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by uspA1”, Molecular Microbiology 48(1):117-129 (2003).
Lafontaine et al., “The UspA1 Protein and a Second Type of UspA2 Protein Mediate Adherence ofMoraxella catarrhalisto Human Epithelial Cells In Vitro”, Journal of Bacteriology, 182(5):1364-1373 (2000).
Meier et al., “The outer membrane proteins UspA1 and UspA2 ofMoraxella catarrhalisare highly conserved in nasopharyngeal isolates from young children”, Vaccine 20:1754-1760 (2002).
Chen et al., “Evaluation of Purified UspA fromMoraxella catarrhalisas a Vaccine in a Murine Model after Active Immunization”, Infection and Immunity 64(6):1900-1905 (1996).
Virji et al., “Carcinoembryonic antigens are targeted by diverse strains of typable and non-typableHaemophilus influenzae”, Molecular Microbiology, 36(4):784-795 (2000).
Virji et al., “Critical determinants of host receptor targeting byNeisseria meningitidesandNeisseria gonorrhoeae: identification of Opa adhesiotopes on the N-domain of CD66 molecules”, Molecular Microbiology, 34(3):538-551 (1999).
Hill et al., “Carcinoembroyonic antigen-related cell adhesion molecule (CEACAM)-binding recombinant polypeptide confers protection against infection by respiratory and urogenital pathogens”, Molecular Microbiology, 55(5):1515-1527 (2005).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Therapeutic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic peptides will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4043577

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.